A novel study has analyzed the cost-effectiveness of different Down syndrome (DS) screening strategies. The result confirms that noninvasive prenatal testing (NIPT) outperforms second-trimester serum screening (STSS) in accuracy and cost-effectiveness, as NIPT identifies twice as many DS cases as STSS.
This article was originally published on MedicalXpress.com